Hepatitis C Therapy: Is It Really Worth It?

Johanson, John F.; Johnson, David
May 1999
American Journal of Gastroenterology;May1999, Vol. 94 Issue 5, p1412
Academic Journal
Presents a study which compared the clinical and economic outcomes of interferon-alpha therapy in patients with chronic hepatitis C virus (HCV) infection. Use of a Markov type decision analysis model to simulate the natural history of HCV infection; Association of an increase in quality adjusted life years with inteferon treatment; Incremental cost-effectiveness of interferon-alpha treatment of HCV infection by age group.


Related Articles

  • Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa. Ali, Sajid; Ali, Ijaz; Azam, Sadiq; Ahmad, Bashir // Virology Journal;2011, Vol. 8 Issue 1, p193 

    Background: Hepatitis C Virus (HCV) genotypes frequency is important for the predication of response to therapy and duration of treatment. Despite variable response rates experienced in the case of Interferon (IFN) -based therapies, there was scarcity of data on HCV genotypes frequency in Khyber...

  • Genomics: Hepatitis C virus gets personal. Iadonato, Shawn P.; Katze, Michael G. // Nature;9/17/2009, Vol. 461 Issue 7262, p357 

    The article attempts to investigate on the effectiveness of human genetic variant in eliminating hepatitis C virus (HCV). According to the authors, there are about 1701 million people are suffering from the infections of hepatitis C virus in the U.S. and European countries and cites that there...

  • IFN Therapy for HCV Can Increase Glomerulopathies.  // Kidney;Nov/Dec99, Vol. 8 Issue 6, p241 

    Focuses on the pathogenesis of proteinuria during interferon (IFN) therapy in patients infected with the hepatitis C virus (HCV). Finding that glomerular deposition of immunoglobulin G or immunoglobulin A and complements in all patients using immunofluorescence; Need for physicians to carefully...

  • Adverse Cutaneous Reactions to Interferon Alfa-2b Plus Ribavirin Therapy in Patients with Chronic Hepatitis C Virus. Manjón-Haces, Joséantonio; Vázquez-López, Francisco; Gómez-Díez, Santiago; Hidalgo-García, Yolanda; Pérez-Alvarez, Ramón; Soler-Sánchez, Tomás; Pérez-Oliva, Narciso // Acta Dermato-Venereologica;Jun/Jul2001, Vol. 81 Issue 3, p223 

    Discusses adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus (HCV). Impact of interferon alfa-2b therapy on patients with HCV; Types of lesions present in patients; Reason provided regarding the need to produce a proper information...

  • Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. Kobayashi, Makoto; Watanabe, Kazumasa; Ishigami, Masatoshi; Murase, Kenichi; Ito, Hiroshi; Ukai, Koji; Yano, Motoyoshi; Takagi, Kenji; Hattori, Masaki; Kakumu, Shinichi; Yoshioka, Kentaro // American Journal of Gastroenterology;Apr2002, Vol. 97 Issue 4, p988 

    OBJECTIVES:The interferon sensitivity-determining region (ISDR) in nonstructural region 5A (NS5A) of hepatitis C virus genotype 1b has been reported to correlate with response to interferon therapy and viral load. Recently the correlation between NS5A and response to interferon in genotype 2a...

  • Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. Furuta, Masahiko; Kaito, Masahiko; Gabazza, Esteban; Fujita, Naoki; Ishida, Satoshi; Tamaki, Shigenori; Ikeda, Ritsuko; Wakisawa, Shinya; Hayashi, Hisao; Watanabe, Shozo; Adachi, Yukihiko // Journal of Gastroenterology;2000, Vol. 35 Issue 1, p60 

    Abstract: Many patients with porphyria cutanea tarda (PCT) have been reported to be hepatitis C virus (HCV) carriers, suggesting that HCV infection plays a role in the pathogenesis of this type of porphyria. In this study, we report a patient with chronic hepatitis C-associated PCT. Therapy with...

  • Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. Arase, Yasuji; Ikeda, Kenji; Tsubota, Akihito; Suzuki, Yoshiyuki; Saitoh, Satoshi; Kobayashi, Masahiro; Kobayashi, Mariko; Suzuki, Fumitaka; Akuta, Norio; Someya, Takashi; Kumada, Hiromitsu // Journal of Gastroenterology;2003, Vol. 38 Issue 2, p158 

    Background In patients with hepatitis C virus (HCV)genotype 1b and a high virus load, of more than 1 Meq/ ml by the DNA probe assay, the clearance of HCVRNA was achieved in only 10% with a 6-month interferon (IFN) course. We therefore assessed the efficacy of prolonged IFN therapy in patients...

  • Peginterferon lambda-1a decreased viral load more quickly, safely vs. alfa-2a in HCV. Taliercio, Adam // Infectious Disease News;Dec2012, Vol. 25 Issue 12, p49 

    The article reports on a study which found a decrease in hepatitis C virus RNA and fewer side effects in noncirrhotic patients with chronic hepatitis C virus who received pegylated interferon lambda-la.

  • Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to... Zein, Nizar N.; Rakela, Jorge // Annals of Internal Medicine;10/15/96, Vol. 125 Issue 8, p634 

    Studies the geographic distribution and clinical significance of hepatitis C virus (HCV) genotypes in the United States. Examination of the influence of HCV genotypes on response to interferon therapy; Predominance of HCV genotypes 1a and 1b in patients with chronic hepatitis C; Absence of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics